COVID-19 Boost As Pharma ROI Hits Heights Not Seen For Seven Years, Finds Deloitte
Expected return on investment for pharma firms jumped sharply to 7% in 2021, driven largely by COVID-19 R&D but even when the pandemic's impact was stripped out, there was an increase in core R&D productivity compared with 2020, a new report from Deloitte has found. The average cost of developing a drug also declined from 2020 to 2021.
You may also be interested in...
The decrease in overall R&D productivity continues – a trend that started in 2018. It would be too easy to attribute this fall in R&D productivity to COVID-19 alone.
The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.
Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.